The Office for Health Improvement and Disparities (OHID) has updated its guidance on potent synthetic opioids, focusing on preparing for future threats posed by these substances. The guidance emphasises the importance of drug testing and screening for surveillance to mitigate harm and enhance public health responses.

Potent Synthetic Opioids: A Growing Concern

Updated Guidance

• Drug Testing to Reduce Harm: The updated guidance includes a new section on drug testing aimed at reducing harm associated with potent synthetic opioids. This addition underscores the need for effective testing strategies to identify and manage the risks posed by these substances.
• Surveillance and Screening: The guidance revises the section on drug testing and screening for surveillance, highlighting the importance of monitoring the presence and impact of synthetic opioids in the illicit drug market.

Incident Planning and Response

• Local Area Preparedness: Local areas are encouraged to use the guidance to prepare their response to incidents involving potent synthetic opioids, such as nitazenes or fentanyl. This involves working through existing emergency preparation mechanisms to develop rapid response plans.
• Risk Assessment and Communication: The guidance outlines steps for local partners to understand the scale of the threat, assess risks, communicate effectively, and take actions to mitigate potential harm.

Implications for Public Health

The updated guidance from OHID is crucial for local health authorities and partners in developing strategies to address the challenges posed by potent synthetic opioids. By focusing on drug testing and surveillance, the guidance aims to enhance the ability of local areas to respond effectively to opioid-related incidents.

Source

DB Recovery Resources